STAT+: The mystery of Moderna’s magic algorithm

STAT PlusBiotech The mystery of Moderna’s magic algorithm Is it the ‘secret sauce’ in the cancer vaccine co-developed with Merck? Manage alerts for this article Email this article Share this article By Jason Mast, Matthew Herper, and Angus ChenAug. 27, 2026 Jason Mast[email protected]Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease.

Confidential tips can be sent on Signal at JasonMast.77.Matthew Herper[email protected]Matthew Herper covers medical innovation — both its promise and its perils.Angus Chen[email protected]Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08. A personalized cancer vaccine developed by Moderna and Merck has generated widespread enthusiasm since the companies announced last week that it had succeeded in a late-stage trial.

If regulators ultimately approve it, the treatment will be a triumph of immunology and cancer biology. But it may also be a triumph of the algorithm.Advertisement The vaccine, intismeran autogene, would be the first approved medicine whose genetic instructions — that is, the individual letters of its mRNA — is determined by a computer. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, Cancer, Merck, Moderna, Pharmaceuticals, STAT+ Submit a correction requestReprints Jason Mast General Assignment Reporter Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease.

Confidential tips can be sent on Signal at JasonMast.77. Matthew Herper Senior Writer, Medicine, Editorial Director of Events Matthew Herper covers medical innovation — both its promise and its perils. Angus Chen Cancer Reporter Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community.

You can reach Angus on Signal at angus.08. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Opinions+ August 27, 2026 STAT Plus: A bill is supposed to protect U.S. biotech from Chinese competition.

But there’s a loophole Biotech August 26, 2026 STAT Plus: FDA approves new pancreatic cancer drug expected to usher in new era of treatment Advertisement The Readout August 26, 2026 STAT Plus: Key data on a new class of cardio drugs are coming AI Prognosis August 26, 2026 STAT Plus: AI biotech Insitro’s Daphne Koller on how to speed up clinical trials Biotech August 25, 2026 STAT Plus: After a years-long slump, Massachusetts biopharma sector has come roaring back in 2026 Subscriber Picks